Qingfei Tongluo Mixture Attenuates Bleomycin-Induced Pulmonary Inflammation and Fibrosis through mTOR-Dependent

Shuyu Ge1, Zhenghong Guo2, Ting Xiao3

  • 1Department of Pharmacy, Zhejiang Academy of Traditional Chinese Medicine, Tongde Hospital of Zhejiang Province, Hangzhou, China.

Mediators of Inflammation
|February 16, 2024
PubMed

Insights

Qingfei Tongluo mixture (QFTL) effectively treats lung fibrosis in rats by reducing inflammation and fibrosis markers. This traditional Chinese medicine shows potential as a new therapy for idiopathic pulmonary fibrosis (IPF).

Area of Science:

  • Pulmonology
  • Pharmacology
  • Cell Biology

Background:

  • Idiopathic pulmonary fibrosis (IPF) is a severe lung disease with limited treatment options.
  • Qingfei Tongluo mixture (QFTL), used for viral pneumonia, may offer protective effects against respiratory diseases.
  • This study investigates QFTL's therapeutic potential for bleomycin-induced IPF in rats.

Purpose of the Study:

  • To evaluate the efficacy of QFTL in a rat model of bleomycin-induced pulmonary fibrosis.
  • To elucidate the underlying mechanism of QFTL's action, focusing on inflammation and autophagy pathways.

Main Methods:

  • Male SD rats were induced with bleomycin and treated with varying doses of QFTL, chloroquine (CQ), or pirfenidone (PFD).
  • Lung tissues and blood samples were analyzed for pathological changes, inflammatory mediators (TGF-β, TNF-α, IL-1β), hydroxyproline (HYP) levels, and protein expression (α-SMA, MMP12, P62, mTOR).
  • Histological, ELISA, hydroxyproline assay, immunohistochemistry, and Western blotting techniques were employed.

Main Results:

  • QFTL treatment significantly improved body weight, lung coefficient, and reduced pathological lung damage in bleomycin-induced rats.
  • QFTL administration decreased levels of pro-inflammatory mediators and hydroxyproline, indicating reduced inflammation and fibrosis.
  • QFTL attenuated the expression of pulmonary fibrosis markers (α-SMA, MMP12) and modulated autophagy proteins (P62, mTOR).
  • The autophagy inhibitor CQ reversed QFTL's beneficial effects on HYP and α-SMA, suggesting QFTL acts via mTOR-dependent autophagy.

Conclusions:

  • Qingfei Tongluo mixture (QFTL) demonstrates significant anti-inflammatory and anti-fibrotic effects in a rat model of pulmonary fibrosis.
  • The therapeutic mechanism involves the modulation of mTOR-dependent autophagy.
  • QFTL holds promise as a potential alternative therapeutic agent for idiopathic pulmonary fibrosis (IPF).

Related Concept Videos